Livongo Health

Reviewed acquired Updated Mar 31, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Mountain View, CA
Founded 2014
Latest Stage IPO
Total Raised $235M
Website https://www.livongo.com
Acquired By Teladoc Health
Sector
digital-health healthcare consumer-health chronic-disease-management

Investors

Hemant Taneja Series A (led) (2014)
Glen Tullman Founder/Seed (2014)
Lee Shapiro Seed (hatched) (2014)
General Catalyst Series A (2014)
Kleiner Perkins Series B (2015)
General Catalyst Series D (2017)
General Catalyst Series E (2018)
7wire Ventures Series C (2016)

Founders

Glen Tullman Founder & Executive Chairman

About

Livongo Health was a digital health company founded in 2014 by Glen Tullman, the former CEO of Allscripts, to help people with chronic conditions manage their health through connected devices and data science 1. Tullman was inspired to start the company after his son Sam was diagnosed with type 1 diabetes 2. The company originated from EosHealth, founded by Dr. Kimon Angelides in 2008, which was acquired by 7wire Ventures in October 2013 and rebranded as Livongo Health 2. Headquartered in Mountain View, California, Livongo’s initial focus was diabetes management, delivering a connected blood glucose meter with real-time coaching and personalized health nudges 1. The company later expanded to address hypertension, weight management, pre-diabetes, and behavioral health 3.

Livongo raised approximately $235 million across five private funding rounds before filing for its IPO on June 28, 2019 4. The company went public on the Nasdaq on July 25, 2019 at $28 per share, raising approximately $355 million in gross proceeds 5. The IPO closed with full exercise of the underwriters’ over-allotment option, bringing total gross proceeds to approximately $408.5 million from 14,590,050 shares 6. Livongo reported 2018 revenue of $68.4 million with a net loss of $33.4 million 4.

On August 5, 2020, Teladoc Health announced a merger with Livongo in a deal valued at approximately $18.5 billion 7. The merger was completed on October 30, 2020, with Livongo shareholders receiving 0.5920 shares of Teladoc Health stock plus $11.33 in cash per Livongo share 8.

Funding History

Date Round Amount Lead Investor(s) Co-Investors
2014-09-10 Series A $10M General Catalyst — 9
2015-04-07 Series B $20M Kleiner Perkins DFJ, General Catalyst 10
2016-04-12 Series C $44.5M — Merck Global Health Innovation Fund, Sapphire Ventures, Zaffre Investments, Cowen Private Investments, Wanxiang America, General Catalyst, Kleiner Perkins, DFJ, 7wire Ventures 1112
2017-03-16 Series D $52.5M General Catalyst, Kinnevik (co-lead) EDBI, American Investment Holdings, Microsoft Ventures 13
2018-04-11 Series E $105M General Catalyst, Kinnevik (co-lead) DFJ, Kleiner Perkins, Merck Global Health Innovation Fund, Microsoft Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Echo Health Ventures 314
2019-07-25 IPO $355M — Nasdaq: LVGO. Underwriters: Morgan Stanley, Goldman Sachs, J.P. Morgan 5

At IPO, General Catalyst held approximately 25.4% of the company, Kinnevik held 12%, Kleiner Perkins held 8.9%, Merck Global Health Innovation Fund held 7.6%, and 7wire Ventures held 7.1%. Founder Glen Tullman personally held 5.1% 415.

What Investors Say

“Livongo has become the market leader by providing a delightful, evidence-based approach for improving quality of life for consumers with diabetes.” — Hemant Taneja, Managing Director, General Catalyst 3

“The strategic relationship announced with Cambia today is indicative of the type of partnership Livongo attracts — defining of a new era in health.” — Chris Bischoff, Senior Investment Director, Kinnevik 3

What Founders Say

“We’re reinventing the way people with chronic conditions, beginning with diabetes, will experience and manage their disease.” — Glen Tullman, Founder & Executive Chairman, at Livongo’s launch 1

“We will build or buy other solutions that will run on our platform.” — Glen Tullman, CEO, on expansion beyond diabetes at Series C announcement 12

Sources

  1. 7wire Ventures, “Glen Tullman Launches Livongo Health to Empower Consumers with Chronic Conditions to Live Better, Beginning with Diabetes,” 2014. https://www.7wireventures.com/news/glen-tullman-launches-livongo-health-to-empower-consumers-with-chronic-conditions-to-live-better-beginning-with-diabetes/↩↩↩

  2. William Weng blog, “History of Livongo: Glen Tullman,” accessed March 2026. https://www.williamweng.com/posts/livongo-series-history-of-livongo-glen-tullman↩↩

  3. Echo Health Ventures, “Livongo Health Raises $105 Million,” April 11, 2018. https://www.echohealthventures.com/news/livongo-health-raises-105-million/↩↩↩↩

  4. Crunchbase News, “HealthTech Startup Livongo Files For IPO With Quick Revenue Growth, Growing Losses,” June 28, 2019. https://news.crunchbase.com/venture/healthtech-startup-livongo-files-for-ipo-with-quick-revenue-growth-growing-losses/↩↩↩

  5. GlobeNewsWire, “Livongo Announces Pricing of Initial Public Offering,” July 25, 2019. https://www.globenewswire.com/news-release/2019/07/25/1887658/0/en/Livongo-Announces-Pricing-of-Initial-Public-Offering.html↩↩

  6. GlobeNewsWire, “Livongo Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares,” July 29, 2019. https://www.globenewswire.com/news-release/2019/07/29/1893207/0/en/Livongo-Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html↩

  7. GlobeNewsWire, “Teladoc Health and Livongo Merge to Create New Standard in Global Healthcare Delivery, Access and Experience,” August 5, 2020. https://www.globenewswire.com/news-release/2020/08/05/2073098/0/en/Teladoc-Health-and-Livongo-Merge-to-Create-New-Standard-in-Global-Healthcare-Delivery-Access-and-Experience.html↩

  8. GlobeNewsWire, “Teladoc Health Completes Merger with Livongo,” October 30, 2020. https://www.globenewswire.com/news-release/2020/10/30/2117764/0/en/Teladoc-Health-Completes-Merger-with-Livongo.html↩

  9. PE Hub, “Livongo Health raises $10 mln Series A,” September 2014. https://www.pehub.com/2014/09/livongo-health-raises-10-mln-series-a/↩

  10. PR Newswire, “Livongo Health Raises $20 Million in Series B Funding From Kleiner Perkins Caufield & Byers, DFJ and General Catalyst,” April 7, 2015. https://www.prnewswire.com/news-releases/livongo-health-raises-20-million-in-series-b-funding-from-kleiner-perkins-caufield–byers-dfj-and-general-catalyst-300061771.html↩

  11. FinSMEs, “Livongo Health Completes $44.5M Series C Financing,” April 12, 2016. https://www.finsmes.com/2016/04/livongo-health-completes-44-5m-series-c-financing.html↩

  12. Modern Healthcare, “Livongo raises $44.5 million in quest to expand beyond diabetes,” April 12, 2016. https://www.modernhealthcare.com/article/20160412/NEWS/160419980/livongo-raises-44-5-million-in-quest-to-expand-beyond-diabetes↩↩

  13. PR Newswire, “General Catalyst and Kinnevik Co-Lead a $52.5 Million Investment in Livongo Health,” March 16, 2017. https://www.prnewswire.com/news-releases/general-catalyst-and-kinnevik-co-lead-a-525-million-investment-in-livongo-health-300424555.html↩

  14. MedCity News, “Livongo rakes in $105M, introduces partnership with Cambia Health Solutions,” April 11, 2018. https://medcitynews.com/2018/04/livongo-105m-cambia/↩

  15. Kinnevik, “Pricing of Livongo’s IPO,” July 2019. https://www.kinnevik.com/investor-relations/press-releases/2019/pricing-of-livongos-ipo/↩